États-Unis · Plateformes & données · Yahoo Finance

Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule

Publié par Yahoo Finance · États-Unis il y a 9 h

Johnson & Johnson (NYSE:JNJ) today announced promising Phase 1 results for JNJ-6143 (formerly HLD-0915), an investigational once-daily oral Regulated Induced Proximity Targeting…

Lire l'article complet sur Yahoo Finance Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finance.yahoo.com)

Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule

À lire aussi

Titan Investment Management LLC Makes New $4.43 Million Investment in Eli Lilly and Company $LLY

Elon Musk Wants to Give Every American Child a Share of SpaceX. Here's What It Would Cost -- and What It Means for Everyone Else Holding the Stock

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Gold prices break $4,000 as investors brace for crucial test

Myro (MYRO) Price Prediction: 2025, 2026, 2030

Gene Munster Says Apple’s $2,200 iPhone Duo Could Add $8B To FY27 Revenue, Sees 20M Units In Sales Even As Wall Street Expects Only 12M

Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule

Partager

À lire aussi

Titan Investment Management LLC Makes New $4.43 Million Investment in Eli Lilly and Company $LLY

Elon Musk Wants to Give Every American Child a Share of SpaceX. Here's What It Would Cost -- and What It Means for Everyone Else Holding the Stock

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Gold prices break $4,000 as investors brace for crucial test

Myro (MYRO) Price Prediction: 2025, 2026, 2030

Gene Munster Says Apple’s $2,200 iPhone Duo Could Add $8B To FY27 Revenue, Sees 20M Units In Sales Even As Wall Street Expects Only 12M